/
TCRT
$2.35-$0.02 (-1.05%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.1M
2M shares
52-week range
$1.67 – $6.20
15% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.27%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-121.43
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $146.0K | $0 | $0 | $398.0K | $2.9M | $5.0K | $10.0K | $5.0K |
| Cost of revenue | $0 | $629.0K | $1.1M | $0 | $0 | $4.8M | $0 | $0 |
| Gross profit | $146.0K | −$629.0K | −$1.1M | $398.0K | $2.9M | −$4.8M | $10.0K | $5.0K |
| Gross margin | 100.0% | — | — | 100.0% | 100.0% | -95960.0% | 100.0% | 100.0% |
| R&D | $34.1M | $38.3M | $52.7M | $49.6M | $25.0M | $16.3M | $362.0K | $1.4M |
| Operating income | −$53.9M | −$57.9M | −$80.4M | −$77.5M | −$35.1M | −$34.3M | −$4.8M | −$4.2M |
| EBITDA | −$53.3M | −$117.2M | −$78.8M | −$75.0M | −$31.8M | −$30.9M | −$4.7M | −$4.2M |
| Net income | −$53.1M | −$117.8M | −$80.0M | −$78.8M | −$37.7M | −$35.1M | −$4.7M | −$4.2M |
| Net margin | -36381.5% | — | — | -19786.7% | -1291.2% | -702800.0% | -46790.0% | -83520.0% |
| EPS (diluted) | -55.44 | -158.90 | -56.42 | -53.80 | -25.97 | -21.97 | -2.92 | -2.20 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $88M | $-21.00 | $-21.00–$-21.00 | 1 |
| 2027 | $220M | $-18.00 | $-18.00–$-18.00 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.31
Price
$2.35
Implied downside
-87%
Peer comparison
Alaunos Therapeutics, Inc. Common Stock
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
www.alaunos.com- Employees
- 1
- IPO / List date
- Aug 24, 2005
- HQ
- FORT LAUDERDALE, FL
Held by traders on TradeandTell
No one on the platform currently holds TCRT.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in TCRT as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-07-18 | 1-for-10reverse |
| 2024-02-01 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded TCRT yet.
